Michael Gelband’s CONMED CNMD Stock Holding History

Michael Gelband’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$415K	Sell	12,672 -19,449	-61%	-$700K	﹤0.01%	1286
2026 Q1	$1.14M	Buy	+32,121	New	+$1.31M	0.01%	963
2025 Q3	–	Sell	-12,006	Closed	-$625K	–	1600
2025 Q2	$625K	Sell	12,006 -5,471	-31%	-$300K	0.01%	1090
2025 Q1	$1.05M	Buy	+17,477	New	+$1.13M	0.01%	906
2024 Q2	–	Sell	-31,547	Closed	-$2.53M	–	1586
2024 Q1	$2.53M	Buy	+31,547	New	+$2.81M	0.02%	614
2023 Q4	–	Sell	-41,075	Closed	-$4.14M	–	1546
2023 Q3	$4.14M	Buy	41,075 +21,402	+109%	+$2.46M	0.04%	424
2023 Q2	$2.67M	Buy	19,673 +9,149	+87%	+$1.12M	0.02%	695
2023 Q1	$1.09M	Buy	+10,524	New	+$1.02M	0.01%	1112
2021 Q3	–	Sell	-7,579	Closed	-$1.04M	–	2182
2021 Q2	$1.04M	Buy	+7,579	New	+$1.04M	0.01%	992
2021 Q1	–	Sell	-9,678	Closed	-$1.08M	–	2165
2020 Q4	$1.08M	Sell	9,678 -23,657	-71%	-$2.24M	0.01%	808
2020 Q3	$2.62M	Buy	+33,335	New	+$2.72M	0.05%	323
2020 Q1	–	Sell	-2,674	Closed	-$299K	–	1147
2019 Q4	$299K	Sell	2,674 -7,854	-75%	-$837K	0.01%	1148
2019 Q3	$1.01M	Buy	10,528 +4,159	+65%	+$390K	0.04%	390
2019 Q2	$545K	Buy	+6,369	New	+$524K	0.02%	425

Other funds holding CNMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Michael Gelband's CNMD Position: Q2 2026 in Review

Michael Gelband reduced its CONMED (CNMD) stake by 61% in Q2 2026, selling an estimated $700K and leaving 12,672 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

Michael Gelband first reported a position in CNMD in Q2 2019 and has held it in 14 quarters since. The position peaked at $4.14M in Q3 2023. 245 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

Michael Gelband held 12,672 shares of CONMED worth $415K as of Q2 2026.
Michael Gelband sold 19,449 CONMED shares in Q2 2026, an estimated $700K.
CONMED made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1286 holding.
Michael Gelband first reported a position in CONMED in Q2 2019 and has held it in 14 quarters since.
Michael Gelband's CONMED position peaked at $4.14M in Q3 2023.
245 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.